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Safety of Fertility-Sparing Surgery in Primary Mucinous Carcinoma
of the Ovary
Purpose
The aim of this study is to evaluate the safety of fertility-sparing surgery as the treatment
for patients with primary mucinous epithelial ovarian cancer.
Materials and Methods
A retrospective study of patients with mucinous ovarian cancer between 1991 and 2010
was performed. The demographics and survival outcomes were compared between patients
who underwent fertility-sparing surgery and those who underwent radical surgery. 
Results
A total of 110 patients underwent primary surgery. At the time of surgery, tumors appeared
to be grossly confined to the ovaries in 90 patients, and evidence of metastasis was definite
in 20 patients. Of the 90 patients with tumors that appeared to be grossly confined to the
ovaries at surgical exploration, 35 (38.9%) underwent fertility-sparing surgery. The Kaplan-
Meier curve and the log rank test showed no difference in either recurrence-free survival
(p=0.792) or disease-specific survival (p=0.706) between the two groups. Furthermore,
there was no significant difference in recurrence-free survival (p=0.126) or disease-specific
survival (p=0.377) between the two groups, even when the analysis was limited to women
below the age of 40. In a multivariate Cox model, fertility-sparing surgery had no effect on
either recurrence-free survival (recurrence hazard ratio [HR], 1.20; 95% confidence interval
[CI], 0.25 to 5.71) or disease-specific survival (death HR, 0.88; 95% CI, 0.17 to 4.60).
Conclusion
Fertility-sparing surgery in primary mucinous cancer grossly confined to the ovaries may be
a safe option and one not associated with an increase in recurrence or mortality. 
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Introduction
Epithelial ovarian cancer is the most lethal of the gyneco-
logic cancers. Approximately 20% of all epithelial ovarian
cancer are diagnosed at an early stage, and thus high survival
rates have been reported for patients whose disease was
identified at this stage [1]. Moreover, approximately 10% of
all epithelial ovarian cancer occurs in women under the age
of 40 years [2]. The safety of fertility-sparing surgery for
women of childbearing age with early-stage disease has been
evaluated over the past two decades [3-11]. The current
guidelines recommend fertility-sparing surgery only in
selected cases of early-stage ovarian cancer [12].
Primary mucinous carcinoma of the ovary accounts for 7%
to 14% of all invasive epithelial ovarian cancers [13]. When
compared to high-grade serous carcinoma, mucinous carci-
noma has distinct presentation, clinical course, and response
to therapy [14]. Moreover mucinous carcinoma is usually
confined to the ovary at surgery, and the prognosis is favor-
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able when found at an early stage [15]. For mucinous tumors
apparently confined to the ovary, some studies have
reported that complete surgical staging is unnecessary due
to a low risk of upstaging [16,17]. Despite the infrequency of
this subtype, previous studies have shown that about 27% of
patients with stage I epithelial ovarian cancer have mucinous
histology [18,19]. In Korea, mucinous carcinoma is the most
common histologic subtype of stage I epithelial ovarian
cancer [16]. Because early-stage mucinous carcinoma is
usually found in young women [7-11], fertility preservation
is a matter of great interest in considering mucinous tumors
than for other histologic subtypes. However, the safety of
fertility-sparing surgery in mucinous histology has not yet
been determined.
In this study, we compare the long-term oncologic out-
comes of fertility-sparing surgery with those of radical sur-
gery in patients with apparent early-stage mucinous
carcinoma.
Materials and Methods
1. Patients
After receiving approval from the Institutional Review
Board, we reviewed all patients with primary mucinous
carcinoma of the ovary diagnosed at Seoul National Univer-
sity Hospital between January 1991 and December 2010. A
gynecologic oncology pathologist evaluated all cases.
Patients with borderline malignancies or with metastatic
mucinous ovarian carcinomas from other primary sites were
excluded. Histological diagnosis was established according
to the World Health Organization (WHO) classification.
Clinical and pathologic variables, such as age, Interna-
tional Federation of Gynecology and Obstetrics (FIGO) stage,
year of diagnosis, grade, adjuvant chemotherapy, surgical
procedure, and date of last contact or date of recurrence/
death, were collected. In addition, we gathered information
on the cause and date of death from death certificates
obtained from the Korean National Statistical Office. 
2. Treatment methods
Fertility-sparing surgery was performed if patients of
childbearing age had a strong desire to retain fertility. These
women were informed of the possible risks and benefits of
fertility-sparing surgery and signed a consent form during a
preoperative counseling session. Patients in the fertility-spar-
ing surgery group underwent unilateral salpingo-oophorec-
tomy on the side of the ovarian tumor with surgical explo-
ration (cytology of peritoneal washing or ascites, careful
palpation and inspection of the peritoneal cavity). Surgical
staging procedures, such as peritoneal biopsy of suspicious
lesions or random biopsy, appendectomy, omentectomy, and
lymphadenectomy, were optional and conducted at the
surgeon’s discretion. Otherwise, patients were categorized
as being in the radical surgery group. 
Adjuvant chemotherapy is based on the pathologic find-
ings of the surgical specimen. Patients with stage IAG3 or
IBG3, or any grades of IC, were treated with three to six
courses of platinum-based chemotherapy. Two patients did
not receive adjuvant chemotherapy despite indication.
3. Statistical analysis
Disease-specific survival was defined as the time from
surgery to the date of death due to ovarian cancer. Recur-
rence-free survival was defined as the time from surgery to
the date of recurrence. 
The differences between clinical and demographic charac-
teristics of the fertility-sparing surgery and radical surgery
groups were compared with Student’s t-test for continuous
variables and chi-square test or Fisher’s exact test for cate-
gorical variables. The recurrence-free and disease-specific
survival curves were estimated using the Kaplan-Meier
method, and the differences in survival between the groups
were compared using the log rank test. Cox proportional
hazards models were developed to examine the survival. In
Cox proportional hazards analyses, the recurrence and death
hazard ratios (HRs) were modeled and patients who under-
went fertility preservation were compared with those who
did not. All analyses were performed using STATA ver. 11.0
(StataCorp, College Station, TX). All p-values are two-sided.
Results
1. Patient characteristics 
In total, 110 patients with mucinous epithelial ovarian
cancer were identified in our cancer registry, all of which had
undergone primary surgery. At the time of surgery, 90
patients (81.8%) had tumors grossly confined to the ovaries,
and 20 patients (18.2%) had definite evidence of metastasis.
Of the 90 patients with tumors grossly confined to the
ovaries, 35 patients (38.9%) underwent fertility-sparing
surgery based on the surgeon’s decision. 
The baseline characteristics are shown in Table 1. The
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Table 1. Clinical and demographic characteristics
Fertility-sparing surgery
p-value
Yes (n=35) No (n=55)
Age (yr) 28.6?10.1 50.3?14.0 < 0.001
Stage 0.496
IA 21 (60) 34 (61.8)
IB 0 (0) 1 (1.8)
IC 13 (37.1) 17 (30.9)
IIA 0 (0) 1 (1.8)
IIB 0 (0) 2 (3.6)
IIC 1 (2.9) 0 (0)
Year of diagnosis 0.067
1991-2000 15 (42.9) 18 (32.7)
2001-2005 13 (37.1) 13 (23.6)
2006-2010 7 (20.0) 24 (43.6)
Adjuvant chemotherapy 0.498
Yes 14 (40.0) 26 (47.3)
Conventional platinum-based 5 (14.3) 9 (16.4)
Taxane plus platinum 9 (25.7) 17 (30.9)
No 21 (60.0) 29 (52.7)
Grade 0.479
1 27 (77.1) 34 (61.8)
2 5 (14.3) 15 (27.3)
3 1 (2.9) 2 (3.6)
NA 2 (5.7) 4 (7.3)
Recurrence (%) 0.923
Yes 6 (17.1) 9 (16.4)
No 29 (82.9) 46 (83.6)
Values are presented as mean?standard deviation or number (%). NA, not available.
Table 2. Procedures performed during surgical staging and cases of microscopic metastasis after surgery (cases of
metastasis/cases of surgery performed)
Fertility-sparing surgery
Yes (n=35) No (n=55)
Hysterectomy 0/0 0/55
Contralateral oophorectomy 0/0 0/49a)
Peritoneal biopsy 1/7 3/20
Appendectomy 0/9 0/41
Omentectomy 0/12 0/45
Lymphadenectomy 0/2 0/26
Cytology 6/35 2/55
a)Among patients who had tumors grossly confined to unilateral ovary at the time of surgery.
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mean age at diagnosis was 28.6 years in the fertility-sparing
surgery group and 50.3 years in the radical surgery group
(p < 0.001). With the exception of age, the clinical character-
istics were similar for both groups, including stage, year of
diagnosis, adjuvant chemotherapy, tumor grade, and recur-
rence rate.
2. Upstaging after surgical staging
Table 2 shows the procedures performed at the time of
surgical exploration and cases of microscopic metastasis after
additional biopsies. Surgical staging led to upstaging for four
patients who were identified as having invasive cancer
following a peritoneal biopsy of a suspicious lesion or adhe-
sion site. However, there were not any cases with upstaging
occurrence based on random peritoneal biopsies without
suspicious lesions. In addition, a positive peritoneal washing
cytology was identified in eight patients. Among these
patients, ovarian surface involvement or spontaneous
rupture had already been identified in three cases, intraop-
erative rupture occurred in two patients, and invasive cancer
was found following peritoneal biopsy in one patient. There-
fore, only two patients were upstaged based solely on wash-
ing cytology, both of which were in the fertility-sparing
surgery group. There was no case of upstaging following
lymphadenectomy, appendectomy, omentectomy, or hyster-
ectomy. Moreover, of the 49 patients who had tumors that
were unilateral and confined to the ovary at the time of
surgery in the radical surgery group, no tumor was identi-
fied on the opposite ovary following bilateral salpingo-
oophorectomy. 
3. Survival analysis
The median follow-up duration was 104 months (range,
8.0 to 231.6 months). The Kaplan-Meier curves and the log
rank test showed no difference in either recurrence-free
survival (p=0.792) or disease-specific survival (p=0.706)
between patients who underwent fertility-sparing surgery
and radical surgery (Fig. 1). Five-year disease-specific
survival was 91.3% for those who had fertility-sparing
surgery, compared with 86.4% for patients who underwent
radical surgery. In addition, 10-year disease-specific survival
was 81.4% for those who had fertility-sparing surgery,
compared with 81.8% for patients who underwent radical
surgery.
Of the 90 patients with tumors that appeared to be grossly
confined to the ovaries upon surgical exploration, 15 (16.7%)
Table 3. Cox proportional hazards model of factors associated with recurrence and disease-specific survival for primary
mucinous cancer grossly confined to the ovaries
Recurrence HR (95% CI) Death HR (95% CI)
FSS
No Reference Reference
Yes 1.20 (0.25-5.71) 0.88 (0.17-4.60)
Age (yr)
< 40 Reference Reference
! 40 2.08 (0.38-11.55) 1.04 (0.18-6.08)
Stage
IA or IB Reference Reference
IC 1.98 (0.46-8.61) 1.56 (0.35-7.03)
II 28.99 (2.72-308.91) 11.47 (1.16-113.17)
Year of diagnosis
1991-2000 Reference Reference
2001-2005 0.53 (0.12-2.31) 0.24 (0.04-1.56)
2006-2010 0.14 (0.01-1.33) 0.29 (0.04-2.17)
Adjuvant chemotherapy
No Reference Reference
Yes 2.24 (0.48-10.46) 1.86 (0.39-8.83)
Grade
1 Reference Reference
2 1.35 (0.27-6.78) 1.40 (0.25-7.98)
3 3.09 (0.25-37.76) 9.26 (0.60-141.82)
HR, hazard ratio; CI, confidence interval; FSS, fertility-sparing surgery.
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eventually experienced disease recurrence, including six of
the 35 patients (17.1%) who underwent fertility-sparing
surgery and nine of the 55 patients (16.4%) who underwent
radical surgery (p=0.923). Contralateral adnexal recurrence
was suspected in just one of the patients with recurrence in
the fertility-sparing surgery group, based on imaging study
findings. Only two of the 15 patients who experienced recur-
rence went on to live without the disease. 
A subgroup analysis was performed with women below
the age of 40; there were 32 patients in the fertility-sparing
surgery group and 11 in the radical surgery group. Even
when the analysis was confined to women less than 40 years
old, Kaplan-Meier curves and the log rank test showed no
difference in either recurrence-free survival (p=0.126) or
disease-specific survival (p=0.377) between the two groups
(Fig. 2).
Fig. 2. Recurrence-free survival (A) and disease-specific survival (B) in all patients under the age of 40 with tumors grossly
confined to the ovaries.
Fig. 1. Recurrence-free survival (A) and disease-specific survival (B) in all patients with tumors grossly confined to the
ovaries.
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Cox proportional hazards analysis was performed to
adjust for the baseline characteristics (Table 3). Fertility-spar-
ing surgery had no effect on either recurrence-free survival
(HR, 1.20; 95% confidence interval [CI], 0.25 to 5.71) or
disease-specific survival (HR, 0.88; 95% CI, 0.17 to 4.60).
Stage was the most important prognostic factor for recur-
rence and survival in our cohort. This finding did not change
when the analysis was confined to women younger than 40.
The surgical procedure was not an independent prognostic
factor for either recurrence-free survival (HR, 0.22; 95% CI,
0.04 to 1.24) or disease-specific survival (HR, 0.52; 95% CI,
0.09 to 3.11) in patients below the age of 40.
Discussion
This study highlights the safety of fertility-sparing surgery
in cases of mucinous epithelial ovarian cancer when tumors
appear to be grossly confined to the ovaries. We compared
the oncologic outcomes of patients who underwent fertility-
sparing and radical surgery using long-term follow-up data.
In addition, the risk of upstaging is minimal in patients with
early-stage mucinous ovarian cancer when no suspicious
lesions on the peritoneum are found during careful intraop-
erative exploration. 
Previous studies have reported the outcomes of fertility-
sparing surgery in women with early-stage epithelial ovarian
cancer [3-11]. The preservation of the female reproductive
organ is one of the key issues for young women with epithe-
lial ovarian cancer, and in particular for nulliparous women.
However, the criteria for guaranteeing the safety of fertility-
sparing surgery in early-stage ovarian cancer have not been
identified thus far. Although the current guidelines recom-
mend that fertility-sparing surgery may be considered in
selected cases, it is not clear what these ‘selected cases’ are
[12]. Most studies propose that fertility-sparing surgery can
be performed on all young women with stage IA grade 1
ovarian cancer [20]. In many of the above-mentioned series,
fertility-sparing surgery was also performed on invasive
ovarian cancer patients with unfavorable grades, as well 
as on patients with disease not confined to one ovary
[7,8,10,11,21]. Although the recurrence rate remains low even
for these patients, the data has limitations due to the retro-
spective nature of this study and the small sample size.
Recent studies have demonstrated that epithelial ovarian
cancer is not a single disease but is composed of a diverse
group of tumors. Based on distinctive morphologic and
molecular genetic features, a dualistic model that classifies
various types of ovarian cancer into two groups (type I and
type II) was proposed by Kurman and Shih [22]. Type I
tumors are clinically indolent and usually present with
low-grade carcinoma, including low-grade serous, low-grade
endometrioid, and mucinous carcinoma. Mucinous carci-
noma is indolent and has an excellent prognosis when iden-
tified at an early stage [23]. By contrast, advanced-stage
mucinous ovarian cancer has a poor prognosis due to its
resistance to platinum-based chemotherapy [24]. In particu-
lar, mucinous invasive ovarian cancer is a different disease
entity and has distinct characteristics compared to high-
grade serous carcinoma. Therefore, these favorable histologic
subtypes should be distinguished from others. 
In patients with mucinous ovarian cancer grossly confined
to the ovaries, the risk of upstaging after surgical staging
procedure has been reported to be minimal [16,17]. In addi-
tion, these histological subtypes are commonly found in
younger women. As a result, fertility preservation is an
important consideration in this disease subset. Of the 90
patients in our cohort with tumors grossly confined to the
ovaries, only six cases were upstaged following surgical stag-
ing, and there were no cases of upstaging due to microscopic
metastasis following omentectomy, appendectomy, or
lymphadenectomy. This finding was in accordance to those
of previous studies. Recently, a number of studies have
reported that occult lymph node metastasis was not found
in any patients with apparent early-stage mucinous epithelial
ovarian cancer [16,17]. Cho et al. [16] reported that out of 85
patients with stage I mucinous epithelial ovarian cancers,
only five were upstaged due to positive peritoneal cytology.
Schmeler et al. [17] demonstrated that 13 out of 93 patients
with mucinous tumors grossly confined to the ovary were
upstaged based on additional biopsies at the time of surgery.
Moreover, they reported no significant difference in survival
between the group that underwent lymphadenectomy and
the group that did not.
When considering previously described indolent aspects
of early-stage mucinous adenocarcinoma, fertility-sparing
surgery may be an acceptable option for younger women.
However, concerns surrounding suboptimal surgery remain.
One major concern with fertility-sparing surgery is the very
small or microscopic foci involvement of the normal-looking
uterus and contralateral ovary. Previous studies have shown
that the risk of contralateral ovary involvement during
surgery and recurrence in the contralateral residual ovary is
low. Considering the 118 normal-appearing ovaries of
epithelial ovarian cancer patients, Benjamin et al. [25]
reported that only three patients (2.5%) had microscopic
involvement in the contralateral ovary. Moreover, of the 209
patients treated conservatively, 14 patients (6.7%) experi-
enced recurrence in the contralateral ovary [20]. Our results
suggest more promising findings in mucinous histological
subtypes. No cases of upstaging due to microscopic metas-
tasis were identified in our cohort after hysterectomy. Of the
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patients with tumors confined to one ovary at surgical explo-
ration in the radical surgery group, 49 underwent bilateral
salpingo-oophorectomy, where no tumor was identified on
the contralateral ovary. Moreover, of the 35 patients who
underwent fertility-sparing surgery, only one experienced
recurrence in the contralateral ovary. As a result, preserva-
tion of the uterus and contralateral ovary should be consid-
ered in patients with mucinous tumors confined grossly to
one ovary.
Our study is limited by retrospective data collection, a long
study period, small sample size, and possible referral bias.
Moreover, varying surgical treatment types were used at the
clinician’s discretion. Finally, it is unclear whether the lack
of significant differences in recurrence and survival between
patients who underwent fertility-sparing surgery and those
who had radical surgery is attributable to our small sample
size. However, only a small proportion of patients with
invasive epithelial ovarian cancer underwent fertility-spar-
ing surgery. In addition, no prospective study on the fertil-
ity-sparing issue in invasive epithelial ovarian cancer has
been designed, and such a study is unlikely to perform a
randomized controlled trial in the near future, due particu-
larly to ethical problems and the anticipated difficulty in
patient recruitment. Given these circumstances, our retro-
spective analysis opens up a discussion of the possibility that
fertility-sparing surgery may be safe in mucinous histology.
Conclusion
In conclusion, our findings demonstrate that fertility-spar-
ing surgery does not appear to have an adverse impact on
the recurrence and survival rates in patients with early-stage
mucinous ovarian carcinoma. This study has useful implica-
tions for physicians counseling patients who want to
preserve their fertility. To validate our results, further large-
scale studies considering a sufficient number of patients with
mucinous histology are required. 
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